Tecvayli — Sales to customers (Note 9)
Johnson & Johnson Tecvayli — Sales to customers (Note 9) increased by 14.8% to $202.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 33.8%, from $151.00M to $202.00M. Over 3 years (FY 2022 to FY 2025), Tecvayli — Sales to customers (Note 9) shows an upward trend with a 254.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market demand, successful commercialization, or expanded clinical adoption of the therapy, while a decrease may signal increased competition, loss of market share, or changes in patient treatment protocols.
Detailed definition
This metric represents the total revenue generated from the sale of the specific pharmaceutical product Tecvayli to exte...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or specialty oncology therapies reported by peer pharmaceutical companies.
jnj_segment_tecvayli_sales_to_customers_note_9Historical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.75M | $3.75M | $3.75M | $3.75M | $63.00M | $94.00M | $112.00M | $126.00M | $133.00M | $135.00M | $135.00M | $146.00M | $151.00M | $166.00M | $177.00M | $176.00M | $202.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | >999% | +49.2% | +19.1% | +12.5% | +5.6% | +1.5% | +0.0% | +8.1% | +3.4% | +9.9% | +6.6% | -0.6% | +14.8% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | >999% | +111.1% | +43.6% | +20.5% | +15.9% | +13.5% | +23.0% | +31.1% | +20.5% | +33.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's tecvayli — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported tecvayli — sales to customers (note 9) of $202.00M in Q1 2026.
- How has Johnson & Johnson's tecvayli — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's tecvayli — sales to customers (note 9) increased by 33.8% year-over-year, from $151.00M to $202.00M.
- What is the long-term trend for Johnson & Johnson's tecvayli — sales to customers (note 9)?
- Over 3 years (2022 to 2025), Johnson & Johnson's tecvayli — sales to customers (note 9) has grown at a 254.8% compound annual growth rate (CAGR), from $15.00M to $670.00M.
- What does tecvayli — sales to customers (note 9) mean?
- The total revenue earned from sales of the Tecvayli pharmaceutical product.